{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:51:47Z","timestamp":1793317907652,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Cancer Research UK and KWF Kankerbestrijding","award":["ref. C38317\/A24043"],"award-info":[{"award-number":["ref. C38317\/A24043"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The presence of extensive ductal carcinoma in situ (DCIS) adjacent to HER2-positive invasive breast cancer (IBC) is often a contra-indication for breast-conserving surgery, even in case of excellent treatment response of the invasive component. Data on the response of DCIS to neoadjuvant systemic treatment (NST) are limited. Therefore, we estimated the response of adjacent DCIS to NST-containing HER2-blockade in HER2-positive breast cancer patients and assessed the association of clinicopathological and radiological factors with response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Pre-NST biopsies were examined to determine presence of DCIS in all women with HER2-positive IBC treated with trastuzumab-containing NST\u2009\u00b1\u2009pertuzumab between 2004 and 2017 in a comprehensive cancer center. When present, multiple DCIS factors, including grade, calcifications, necrosis, hormone receptor, and Ki-67 expression, were scored. Associations of clinicopathological and radiological factors with complete response were assessed using logistic regression models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Adjacent DCIS, observed in 138\/316 patients with HER2-positive IBC, was eradicated after NST in 46% of patients. Absence of calcifications suspicious for malignancy on pre-NST mammography (odds ratio (OR) 3.75; 95% confidence interval (95% CI) 1.72\u20138.17), treatment with dual HER2-blockade (OR 2.36; 95% CI 1.17\u20134.75), a (near) complete response on MRI (OR 3.55; 95% CI 1.31\u20139.64), and absence of calcifications (OR 3.19; 95% CI 1.34\u20137.60) and Ki-67\u2009&gt;\u200920% in DCIS (OR 2.74; 95% CI 1.09\u20136.89) on pre-NST biopsy were significantly associated with DCIS response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>As DCIS can respond to NST containing HER2-blockade, the presence of extensive DCIS in HER2-positive breast cancer before NST should not always indicate a mastectomy. The predictive factors we found could be helpful when considering breast-conserving surgery in these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-021-06235-2","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T06:03:06Z","timestamp":1620108186000},"page":"213-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer"],"prefix":"10.1007","volume":"189","author":[{"given":"Emma J.","family":"Groen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke E. M.","family":"van der Noordaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schaapveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe S.","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritse M.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette S.","family":"van Ramshorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther H.","family":"Lips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Jeanne T. F. D.","family":"Vrancken Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederieke H.","family":"van Duijnhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8940-2676","authenticated-orcid":false,"given":"Jelle","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"issue":"16","key":"6235_CR1","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","volume":"23","author":"AU Buzdar","year":"2005","unstructured":"Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676\u20133685","journal-title":"J Clin Oncol"},{"issue":"1","key":"6235_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1158\/1078-0432.CCR-06-1345","volume":"13","author":"AU Buzdar","year":"2007","unstructured":"Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL et al (2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study. Clin Cancer Res 13(1):228\u2013233","journal-title":"Clin Cancer Res"},{"issue":"9712","key":"6235_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"L Gianni","year":"2010","unstructured":"Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER. Lancet 375(9712):377\u2013384. https:\/\/doi.org\/10.1016\/S0140-6736(09)61964-4","journal-title":"Lancet"},{"issue":"1","key":"6235_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-5219-3","volume":"19","author":"S Chen","year":"2019","unstructured":"Chen S, Liang Y, Feng Z, Wang M (2019) Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis. BMC Cancer 19(1):1\u201315","journal-title":"BMC Cancer"},{"issue":"26","key":"6235_CR5","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1200\/JCO.2016.70.6267","volume":"35","author":"A Urruticoechea","year":"2017","unstructured":"Urruticoechea A, Rizwanullah M, Im SA, S\u00e1nchez Ruiz AC, L\u00e1ng I, Tomasello G et al (2017) Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therap. J Clin Oncol 35(26):3030\u20133038","journal-title":"J Clin Oncol"},{"issue":"6","key":"6235_CR6","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A et al (2016) 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 17(6):791\u2013800","journal-title":"Lancet Oncol"},{"issue":"9","key":"6235_CR7","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24(9):2278\u20132284. https:\/\/doi.org\/10.1093\/annonc\/mdt182","journal-title":"Ann Oncol"},{"issue":"9","key":"6235_CR8","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1245\/s10434-017-5863-x","volume":"24","author":"P Beitsch","year":"2017","unstructured":"Beitsch P, Whitworth P, Baron P, Rotkis MC, Mislowsky AM, Richards PD et al (2017) Pertuzumab\/trastuzumab\/CT versus trastuzumab\/CT therapy for HER2+ breast cancer: results from the prospective neoadjuvant breast registry symphony trial (NBRST). Ann Surg Oncol 24(9):2539\u20132546","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"6235_CR9","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","volume":"19","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentj\u00e9 VO et al (2018) Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19(12):1630\u20131640","journal-title":"Lancet Oncol"},{"issue":"8","key":"6235_CR10","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1245\/s10434-013-2909-6","volume":"20","author":"HC Shin","year":"2013","unstructured":"Shin HC, Han W, Moon HG, Im SA, Moon WK, Park IA et al (2013) Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients. Ann Surg Oncol 20(8):2582\u20132589","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"6235_CR11","first-page":"1","volume":"18","author":"JS Mieog","year":"2007","unstructured":"Mieog JS, Van Der Hage J, van de Velde CJH (2007) Preoperative chemotherapy for women with operable breast cancer (Review ). Cochrane Database Syst Rev 18(2):1\u201363","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"6235_CR12","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.clon.2017.06.003","volume":"29","author":"H Cain","year":"2017","unstructured":"Cain H, Macpherson IR, Beresford M, Pinder SE, Pong J, Dixon JM (2017) Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice. Clin Oncol 29(10):642\u2013652. https:\/\/doi.org\/10.1016\/j.clon.2017.06.003","journal-title":"Clin Oncol"},{"issue":"9","key":"6235_CR13","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/sj.bjc.6605655","volume":"102","author":"H Wong","year":"2010","unstructured":"Wong H, Lau S, Yau T, Cheung P, Epstein RJ (2010) Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Br J Cancer 102(9):1391\u20131396. https:\/\/doi.org\/10.1038\/sj.bjc.6605655","journal-title":"Br J Cancer"},{"issue":"8","key":"6235_CR14","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.ejso.2017.04.011","volume":"43","author":"H Goldberg","year":"2017","unstructured":"Goldberg H, Zandbank J, Kent V, Leonov-Polak M, Livoff A, Chernihovsky A et al (2017) Chemotherapy may eradicate ductal carcinoma in situ (DCIS) but not the associated microcalcifications. Eur J Surg Oncol 43(8):1415\u20131420. https:\/\/doi.org\/10.1016\/j.ejso.2017.04.011","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"6235_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-46309-2","volume":"9","author":"AJ Kole","year":"2019","unstructured":"Kole AJ, Park HS, Johnson SB, Kelly JR, Moran MS, Patel AA (2019) Overall survival is improved when DCIS accompanies invasive breast cancer. Sci Rep 9(1):1\u20139. https:\/\/doi.org\/10.1038\/s41598-019-46309-2","journal-title":"Sci Rep"},{"issue":"2","key":"6235_CR16","first-page":"17","volume":"9","author":"JJ Li","year":"2014","unstructured":"Li JJ, Chen C, Gu Y, Di G, Wu J, Liu G et al (2014) The role of mammographic calcification in the neoadjuvant therapy of breast cancer imaging evaluation. PLoS One 9(2):17\u201319","journal-title":"PLoS One"},{"issue":"1","key":"6235_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10549-016-3862-4","volume":"158","author":"SC Doebar","year":"2016","unstructured":"Doebar SC, van den Broek EC, Koppert LB, Jager A, Baaijens MHA, Obdeijn IMAM et al (2016) Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study. Breast Cancer Res Treat 158(1):179\u2013187","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"6235_CR18","first-page":"1027","volume":"9","author":"W Wu","year":"2002","unstructured":"Wu W, Kamma H, Ueno E, Fujiwara M, Satoh H, Hara H et al (2002) The intraductal component of breast cancer is poorly responsive to neo-adjuvant chemotherapy. Oncol Rep 9(5):1027\u20131031","journal-title":"Oncol Rep"},{"issue":"19","key":"6235_CR19","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1200\/JCO.2006.08.2271","volume":"25","author":"C Mazouni","year":"2007","unstructured":"Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF et al (2007) Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 25(19):2650\u20132655","journal-title":"J Clin Oncol"},{"issue":"7\u20138","key":"6235_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/028418698429964","volume":"37","author":"L Pusztai","year":"1998","unstructured":"Pusztai L, Siddik ZH, Mills GB, Bast RC (1998) Physiologic and pathologic drug resistance in ovarian carcinoma\u2014a hypothesis based on a clonal progression model. Acta Oncol (Madr) 37(7\u20138):629\u2013640","journal-title":"Acta Oncol (Madr)"},{"issue":"10","key":"6235_CR21","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1245\/s10434-015-4753-3","volume":"22","author":"D Holmes","year":"2015","unstructured":"Holmes D, Colfry A, Czerniecki B, Dickson-Witmer D, Francisco Espinel C, Feldman E et al (2015) Performance and practice guideline for the use of neoadjuvant systemic therapy in the management of breast cancer. Ann Surg Oncol 22(10):3184\u20133190","journal-title":"Ann Surg Oncol"},{"key":"6235_CR22","unstructured":"Netherlands Comprehensive Cancer Organization (IKNL) Breast cancer Dutch guideline, version 2.0 authorized 2020. Methodology: evidence based, accountability: NABON. https:\/\/www.oncoline.nl\/borstkanker"},{"issue":"1","key":"6235_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/BF02967551","volume":"9","author":"K Matsuo","year":"2002","unstructured":"Matsuo K, Fukutomi T, Watanabe T, Hasegawa T, Tsuda H, Akashi-Tanaka S (2002) Concordance in pathological response to neoadjuvant chemotherapy between invasive and noninvasive components of primary breast carcinomas. Breast Cancer 9(1):75\u201381","journal-title":"Breast Cancer"},{"issue":"3","key":"6235_CR24","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10549-011-1621-0","volume":"132","author":"G Von Minckwitz","year":"2012","unstructured":"Von Minckwitz G, Darb-Esfahani S, Loibl S, Huober J, Tesch H, Solbach C et al (2012) Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy\/trastuzumab treatment in early breast cancer\u2014results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat 132(3):863\u2013870","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"6235_CR25","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1245\/s10434-019-07533-2","volume":"26","author":"S Sun","year":"2019","unstructured":"Sun S, van la Parra RFD, Rauch GM, Checka C, Tadros AB, Lucci A et al (2019) Patient selection for clinical trials eliminating surgery for HER2-positive breast cancer treated with neoadjuvant systemic therapy. Ann Surg Oncol 26(10):3071\u20133079. https:\/\/doi.org\/10.1245\/s10434-019-07533-2","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"6235_CR26","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1245\/s10434-014-4113-8","volume":"22","author":"BE Adrada","year":"2015","unstructured":"Adrada BE, Huo L, Lane DL, Arribas EM, Resetkova E, Yang W (2015) Histopathologic correlation of residual mammographic microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol 22(4):1111\u20131117","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"6235_CR27","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1245\/s10434-014-3914-0","volume":"21","author":"A Weiss","year":"2014","unstructured":"Weiss A, Lee KC, Romero Y, Ward E, Kim Y, Ojeda-Fournier H et al (2014) Calcifications on mammogram do not correlate with tumor size after neoadjuvant chemotherapy. Ann Surg Oncol 21(10):3310\u20133316","journal-title":"Ann Surg Oncol"},{"issue":"31","key":"6235_CR28","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast. J Clin Oncol 31(31):3997\u20134013","journal-title":"J Clin Oncol"},{"key":"6235_CR29","volume-title":"ACR BI-RADS\u00ae Atlas, breast imaging reporting and data system","author":"C D\u2019Orsi","year":"2013","unstructured":"D\u2019Orsi C, Sickles E, Mendelson E, Morris E et al (2013) ACR BI-RADS\u00ae Atlas, breast imaging reporting and data system. American College of Radiology, Reston"},{"issue":"1","key":"6235_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-015-1664-4","volume":"15","author":"ML Marinovich","year":"2015","unstructured":"Marinovich ML, Macaskill P, Irwig L, Sardanelli F, Mamounas E, von Minckwitz G et al (2015) Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis. BMC Cancer 15(1):1\u201312. https:\/\/doi.org\/10.1186\/s12885-015-1664-4","journal-title":"BMC Cancer"},{"issue":"1","key":"6235_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/bjs.9962","volume":"103","author":"NNY Janssen","year":"2016","unstructured":"Janssen NNY, Nijkamp J, Alderliesten T, Loo CE, Rutgers EJT, Sonke JJ et al (2016) Radioactive seed localization in breast cancer treatment. Br J Surg 103(1):70\u201380","journal-title":"Br J Surg"},{"issue":"3","key":"6235_CR32","first-page":"167","volume":"11","author":"R Holland","year":"1994","unstructured":"Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, Van de Vijver MJ et al (1994) Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11(3):167\u2013180","journal-title":"Semin Diagn Pathol"},{"key":"6235_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/9780470316696","volume-title":"Multiple imputation for nonresponse in surveys","author":"DB Rubin","year":"1987","unstructured":"Rubin DB (1987) Multiple imputation for nonresponse in surveys. Wiley, New York"},{"issue":"8","key":"6235_CR34","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2014","unstructured":"Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M et al (2014) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724\u2013734","journal-title":"N Engl J Med"},{"issue":"51","key":"6235_CR35","first-page":"e9384","volume":"96","author":"M Tao","year":"2017","unstructured":"Tao M, Chen S, Zhang X, Zhou Q (2017) Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Medicine (United States) 96(51):e9384","journal-title":"Medicine (United States)"},{"key":"6235_CR36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2612","author":"M Brand\u00e3o","year":"2020","unstructured":"Brand\u00e3o M, Caparica R, Malorni L, Prat A, Carey LA, Piccart M (2020) What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer? Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2612","journal-title":"Clin Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06235-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06235-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06235-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T07:28:40Z","timestamp":1635146920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06235-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["6235"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06235-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"assertion":[{"value":"20 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Sonke reports receiving institutional research support from AstraZeneca, Merck, Novartis, and Roche and Dr Mann from Siemens Healthineers, Medtronic, Bayer Healthcare, BD, Screenpoint Medical, Seno Medical and Transonic Imaging. For the remaining authors, none were declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study involving human participants was in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the institutional review board of the NKI-AVL.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study used only unidentifiable patient information, and no informed consent was required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}